美国境外接种脊灰疫苗儿童脊灰病毒疫苗接种状态评估与接种指导
本报告汇总美国免疫实践咨询委员会(ACIP)现行脊灰病毒疫苗接种建议,并在三价口服脊灰疫苗(tOPV)切换为二价口服脊灰疫苗(bOPV)的背景下,提供CDC关于评估可能在美国境外接种过脊灰疫苗儿童接种状态并为其接种的指导,以确保其获得对全部三种脊灰病毒类型的保护。该指导不是新政策,不改变ACIP对美国脊灰病毒疫苗接种的建议。
要点
- 美国境外可能接种过脊灰疫苗的儿童应满足ACIP建议,即通过适龄接种IPV或tOPV获得对全部三种脊灰病毒类型的保护。
- 无接种记录表明曾接种上述疫苗时,仅推荐按美国适龄IPV接种程序进行接种或再接种。
- 因2型脊灰病毒抗体检测可及性日益有限,血清学评估免疫不再作为可选方案,因而不再推荐。
核心结论
- 该指导不是新政策,不改变ACIP对美国脊灰病毒疫苗接种的建议;居住在美国的儿童(包括移民和难民)应通过适龄接种IPV或tOPV获得对全部三种脊灰病毒类型的保护。
- 无接种记录表明曾接种IPV或tOPV时,仅推荐按美国适龄IPV接种程序进行接种或再接种。
- 对接种记录缺失或存疑的儿童,血清学评估免疫不再作为可选方案,因而不再推荐,原因是2型脊灰病毒抗体检测可及性日益有限。
研究设计与样本
- 本报告为CDC指导文件,汇总ACIP现行脊灰病毒疫苗接种建议,并提供在tOPV切换为bOPV背景下评估和接种可能在美国境外接种过脊灰疫苗儿童的指导。
主要发现
- 1988年世界卫生大会决议根除脊髓灰质炎;此后WPV病例下降>99.9%,从估计每年350,000例降至2015年两个国家的74例。
- 自2000年起美国仅使用IPV;2013年WHO设定2018年实现无脊灰世界的目标;2015年9月宣布2型WPV eradicated。
- 为消除循环2型疫苗衍生脊灰病毒(cVDPV)感染风险,所有使用OPV的国家于2016年4月同步从tOPV切换为仅含1型和3型脊灰病毒的bOPV。
关键数值与推荐
- 对可能在美国境外接种过脊灰疫苗的儿童,应满足ACIP建议:通过适龄接种IPV或tOPV获得对全部三种脊灰病毒类型的保护。
- 无接种记录表明曾接种IPV或tOPV时,仅推荐按美国适龄IPV接种程序进行接种或再接种。
- 对接种记录缺失或存疑的儿童,不再推荐血清学评估免疫,原因是2型脊灰病毒抗体检测可及性日益有限。
临床怎么用
- 对可能在美国境外接种过脊灰疫苗的儿童,按其接种记录评估是否满足ACIP对全部三种脊灰病毒类型的保护要求;无记录表明曾接种IPV或tOPV时,按美国适龄IPV程序接种或再接种;不再采用血清学评估免疫。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 1988, the World Health Assembly resolved to eradicate poliomyelitis (polio). Since then, wild poliovirus (WPV) cases have declined by >99.9%, from an estimated 350,000 cases of polio each year to 74 cases in two countries in 2015 (1). This decrease was achieved primarily through the use of trivalent oral poliovirus vaccine (tOPV), which contains types 1, 2, and 3 live, attenuated polioviruses. Since 2000, the United States has exclusively used inactivated polio vaccine (IPV), which contains all three poliovirus types (2,3). In 2013, the World Health Organization (WHO) set a target of a polio-free world by 2018 (4). Of the three WPV types, type 2 was declared eradicated in September 2015. To remove the risk for infection with circulating type 2 vaccine-derived polioviruses (cVDPV), which can lead to paralysis similar to that caused by WPV, all OPV-using countries simultaneously switched in April 2016 from tOPV to bivalent OPV (bOPV), which contains only types 1 and 3 polioviruses (5). This report summarizes current Advisory Committee on Immunization Practices (ACIP) recommendations for poliovirus vaccination and provides CDC guidance, in the context of the switch from tOPV to bOPV, regarding assessment of vaccination status and vaccination of children who might have received poliovirus vaccine outside the United States, to ensure that children living in the United States (including immigrants and refugees) are protected against all three poliovirus types. This guidance is not new policy and does not change the recommendations of ACIP for poliovirus vaccination in the United States. Children living in the United States who might have received poliovirus vaccination outside the United States should meet ACIP recommendations for poliovirus vaccination, which require protection against all three poliovirus types by age-appropriate vaccination with IPV or tOPV. In the absence of vaccination records indicating receipt of these vaccines, only vaccination or revaccination in accordance with the age-appropriate U.S. IPV schedule is recommended. Serology to assess immunity for children with no or questionable documentation of poliovirus vaccination will no longer be an available option and therefore is no longer recommended, because of increasingly limited availability of antibody testing against type 2 poliovirus.
引用
- Marin M, Patel M, Oberste S, et al. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28081056. doi:10.15585/mmwr.mm6601a6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。